Bruno Crestani, Martin Kolb
European Respiratory Journal 2022 60: 2201946; DOI: 10.1183/13993003.01946-2022
Extract
Bad luck rarely comes unaccompanied. It was advocated for more than a decade to view idiopathic pulmonary fibrosis (IPF) as a “malignant disease” from looking at its clinical course and prognosis, which is worse than for most common malignancies, except lung and pancreatic cancer [1]. What happens to the unfortunate individuals who develop lung cancer on top of IPF (figure 1) and who may ask their physician “what will bring me down first?”. Strong epidemiological evidence indicates that the fibrotic lung is a preneoplastic condition [2].
More research is needed regarding lung cancer development in patients with lung fibrosis http://bit.ly/3ESXAho
Footnotes
-
Conflict of interest: M. Kolb is site PI in industry-sponsored clinical trials for Roche and Boehringer Ingelheim, and reports grants from Canadian Institute for Health Research, grants and personal fees for advisory board work from Boehringer Ingelheim and Roche Canada, personal fees for advisory board work from Horizon, Algernon, CSL Behring, DevPro, Bellerophon and BMS, personal fees for adjudication committee work from United Therapeutics, personal fees for data monitoring committee work from LabCorp, and a chief editor allowance from the European Respiratory Society, outside the submitted work. B. Crestani reports grants or contracts from BMS, Boehringer Ingelheim and Roche, consultancy fees from Apellis, payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Boehringer Ingelheim, BMS, Roche, Sanofi, Novartis, AstraZeneca and Chiesi, and receipt of equipment, materials, drugs, medical writing, gifts or other services from Translate Bio.
- Received October 6, 2022.
- Accepted October 6, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org
